Fusobacterium necrophorum (F. necrophorum)

Fusobacterium necrophorum is a pleomorphic, non-spore-forming, Gram-negative obligate anaerobic bacterium that serves as a significant human and animal pathogen (StatPearls, 2023). It is primarily recognized as the causative agent of Lemierre's syndrome, a life-threatening condition characterized by septic thrombophlebitis of the internal jugular vein following an oropharyngeal infection (NCBI, 2021). The organism's virulence is driven by the production of a potent leukotoxin, which induces apoptosis in white blood cells, and various proteases that facilitate deep tissue invasion (Journal of Medical Microbiology, 2007). From a therapeutic perspective, F. necrophorum is typically managed with anaerobic-spectrum antibiotics like metronidazole and penicillin, although the emergence of beta-lactamase-producing strains presents a growing clinical challenge (PubMed, 2019). Understanding its role in the angina-thrombosis sequence is critical for early diagnosis and the prevention of metastatic complications such as septic pulmonary emboli (Microbiology Society, 2015).

Other names

Bacillus necrophorusSphaerophorus necrophorusFusiformis necrophorusNecrobacillus

Antibiotics targeting this organism typically act by inhibiting bacterial cell wall synthesis (beta-lactams), disrupting DNA structure and causing strand breakage (nitroimidazoles), or binding to the 50S ribosomal subunit to inhibit protein synthesis (lincosamides).